You just read:

Trovagene Presents Overview of Phase 1b/2 Trial of Onvansertib in Patients with KRAS-Mutated Metastatic Colorectal Cancer (mCRC) at ESMO

News provided by

Trovagene, Inc.

Oct 01, 2019, 08:15 ET